Table 3.
Treatment characteristics.
| Variable | N (%) |
|---|---|
| VMAT approach | |
| Single-arc | 3 (14) |
| Dual-arc | 18 (86) |
| PTV dose-tumor (Gy) | |
| 54 Gy/30 fractions | 20 (95) |
| 50.4 Gy/28 fractions | 1 (5) |
| PTV dose-positive nodes (Gy)- 12 pts | |
| 54 Gy/30 fractions | 0 (0) |
| 50.4 Gy/30 fractions | 12 (100) |
| PTV dose-negative nodes (Gy) | |
| 45 Gy/30 fractions | 20 (95) |
| 42 Gy/30 fractions | 1 (5) |
| Chemotherapy | |
| 5-FU + MMC | 21 (100) |
| Cycles | |
| 1 | 1 (5) |
| 2 | 20 (95) |
| Chemotherapy dose reduction | |
| Yes | 1 (5) |
| No | 20 (95) |
| RT duration (days) | |
| Mean | 46 |
| Range | 38–77 |
Legend: IMRT: intensity-modulated radiotherapy; PTV: planning target volume; N: number; 5-FU: 5-fluorouracil; MMC: mytomicin C; RT: radiotherapy.